The hsp90-binding Antibiotic Geldanamycin Decreases Raf Levels and Epidermal Growth Factor Signaling without Disrupting Formation of Signaling Complexes or Reducing the Specific Enzymatic Activity of Raf Kinase*

(Received for publication, June 28, 1996, and in revised form, October 3, 1996)

Louis F. Stancato Dagger , Adam M. Silverstein Dagger , Janet K. Owens-Grillo Dagger , Yu-Hua Chow §, Richard Jove § and William B. Pratt Dagger

From the Dagger  Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan 48109 and the § Molecular Oncology Program, Moffitt Cancer Center, Tampa, Florida 33612

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

We have expressed the mitogenic signaling proteins Src, Ras, Raf-1, Mek (MAP kinase kinase), and Erk (MAP kinase) in baculovirus-infected Sf9 insect cells in order to study a potential role for the chaperone hsp90 in formation of multiprotein complexes. One such complex obtained by immunoadsorption with anti-Ras antibody of cytosol prepared from cells simultaneously expressing Ras, Raf, Mek, and Erk contained Ras, Raf, and Erk. To detect directly the protein-protein interactions involved in forming multiprotein complexes, we combined cytosols from single infections in vitro in all possible combinations of protein pairs. We detected complexes between Ras·Raf, Ras·Src, Raf·Mek, and Raf·Src, but no complex containing Erk was obtained by mixing cytosols. Thus, cellular factors appear to be required for assembly of the Erk-containing multiprotein complex. One cellular factor thought to be involved in signaling protein complex formation is the chaperone hsp90, and we show that Src, Raf, and Mek are each complexed with insect hsp90. Treatment of Sf9 cells with geldanamycin, a benzoquinone ansamycin that binds to hsp90 and disrupts its function, did not decrease coadsorption of either Raf or Erk with Ras, although it did decrease the level of cytosolic Raf. To study geldanamycin action, we treated rat 3Y1 fibroblasts expressing v-Raf and showed that the antibiotic blocked assembly of Raf·hsp90 complexes at an intermediate stage of assembly where Raf is still bound to the p60 and hsp70 components of the assembly mechanism. As in Sf9 cells, Raf levels decline with geldanamycin treatment of 3Y1 cells. To determine if geldanamycin affects mitogenic response, we treated HeLa cells with epidermal growth factor (EGF) and showed that geldanamycin treatment decreased EGF signaling and decreased the level of Raf protein without affecting the EGF-mediated increase in Raf kinase activity. We conclude that hsp90 is not required for forming complexes between the mitogenic signaling proteins or for Raf kinase activity and that EGF signaling is decreased indirectly by geldanamycin because the antibiotic increases degradation of Raf and perhaps other components of the signaling pathway.


INTRODUCTION

Several receptors for polypeptide ligands, including those for insulin, epidermal growth factor, platelet-derived growth factor, and nerve growth factor, transduce signals by activating the mitogen-activated protein (MAP)1 family of serine/threonine kinases (also called Erks for extracellular signal-regulated kinases) (see Refs. 1 and 2, for review). The receptors themselves are tyrosine kinases that undergo ligand-induced autophosphorylation leading to the recruitment of the Grb2 adaptor and its associated Ras activator protein Sos. Subsequent Ras binding to the Raf-1 serine/threonine kinase leads to phosphorylation by Raf-1 of another kinase called Mek (also called MAP kinase kinase), which in turn, phosphorylates and activates Erk. Erk is a terminal effector of this signal transduction pathway in that it can directly phosphorylate transcription factors that regulate gene expression. The receptor-mediated signaling system can be short circuited in the sense that the oncoprotein Src can activate Raf-1 (3-5).

A question that has not been resolved is the extent to which the proteins Ras, Src, Raf, Mek, and Erk exist in a multiprotein complex(es) with each other, an association that might greatly enhance the efficiency of signal transduction. Using either in vitro binding assays or the two-hybrid system, it has been shown that Ras interacts directly with Raf (6-9). Direct interactions between Raf and Mek (8, 10) and between Raf and Src (11) have also been demonstrated. In addition to these binary interactions, a native ternary Ras·Raf·Mek complex has been demonstrated using the two-hybrid system (8) and a similar complex has been formed in vitro by incubating immobilized Ras with brain cytosol (12). Importantly, in the latter case, immobilized Ras·GMP-PNP was incubated with cytosol and the washed sedimented pellet was shown to phosphorylate myelin basic protein and to release soluble MAP kinase (12). These observations are consistent with the possibility of a quaternary Ras·Raf·Mek·Erk signaling complex.

In addition to associations with other components of the MAP kinase signal transduction pathway, Src and Raf exist in native complexes with components of a heat shock protein (hsp) chaperone system. As soon as it is translated, Src becomes associated with hsp90 and a 50-kDa protein (p50) of unknown function (Refs. 13-15, see Ref. 16, for review). The Src·hsp90· p50 heterocomplex can be formed in vitro using a multicomponent protein folding system present in reticulocyte lysate (17, 18). Similarly, Raf exists in a native heterocomplex with hsp90 and p50 (19, 20) that can be reconstituted by the protein folding system of reticulocyte lysate (19). As with the steroid receptors, the Raf·hsp90 heterocomplexes may also contain an immunophilin chaperone of the FK506 binding class (21). The protein folding system that forms these heterocomplexes itself exists in multiprotein complexes consisting of hsp90 bound to various amounts of hsp70, a 60-kDa stress-related protein, and a conserved and widely distributed 23-kDa protein (for review, see Refs. 22 and 23). The hsp90 and its associated proteins act as a self-sufficient protein folding machine (24, 25) that has recently been reconstituted from purified components (26).

To date, it is not known whether reversible protein-protein interactions between the components of the signaling system are sufficient to form the binary complexes and the higher order ternary and quaternary complexes that have been detected, or whether cellular factors like the hsp90 chaperone system participate in complex formation. Experiments with the antibiotic geldanamycin that were recently reported by Schulte et al. (27) suggest that hsp90 is required for Raf·Ras association. Geldanamycin is a benzoquinone ansamycin that was found to revert transformation induced in cultured cells by Src and some other oncogenic tyrosine kinases (28, 29). Geldanamycin does not inhibit kinase activity (29), but it binds in a pharmacologically specific manner to hsp90 and inhibits Src·hsp90 heterocomplex formation in reticulocyte lysate (30). Schulte et al. (27) found that a 4-h treatment of human MCF7 breast cancer cells with 2 µM geldanamycin disrupted multiprotein complexes containing Raf, Ras, and hsp90. This was accompanied by a marked decrease in the half-life of the Raf protein through an increased rate of its degradation (27). It was concluded that hsp90 was required for maintenance of the Raf·Ras complex and for protecting Raf from degradation. Although a negative impact on Raf function was predicted, Raf function itself was not assayed.

In this work we have expressed Src, Ras, Raf, Mek, and Erk singly and in combination in baculovirus-infected Sf9 insect cells. When expressed singly, Mek, like Src and Raf, is in a native complex with hsp90. Cytosols from single infections were combined in vitro in all possible combinations of protein pairs and immunoadsorbed with antibodies against each member of the pair. By this coimmunoadsorption protocol we detect the Ras·Raf, Raf·Mek, and Raf·Src complexes referred to above as well as an unanticipated interaction between Ras and Src. When Sf9 cells are simultaneously infected with baculoviruses encoding Ras, Raf, Mek, and Erk, Ras·Raf·Erk complexes are immunoadsorbed with anti-Ras antibody. No complex containing Erk can be obtained by mixing any combination of cytosols from single infections, suggesting that cellular factors are required to produce a multiprotein complex containing Erk. Although treatment of Sf9 cells for 4 h with 10 µM geldanamycin causes a decrease in the amount of cytosolic Raf, it does not decrease recovery of Ras·Raf·Erk complexes. The mechanism of the geldanamycin effect is further explored in rat 3Y1 cells stably expressing v-Raf where we show the antibiotic blocks assembly of mature Raf·hsp90 complexes and decreases Raf levels. We also show that geldanamycin inhibits signaling through the EGF receptor in HeLa cells, but the inhibition can be accounted for by the ability of the antibiotic to decrease the level of Raf and perhaps the levels of other components of the signaling pathway.


EXPERIMENTAL PROCEDURES

Materials

125I-Conjugated goat anti-mouse and anti-rabbit IgGs were from DuPont NEN. Nuclease-treated rabbit reticulocyte lysate was from Promega. Protein A-Sepharose and goat anti-mouse and anti-rabbit IgG horseradish peroxidase conjugates were from Sigma. The rabbit antiserum against hsp70 and hsp90 (31) was a generous gift from Dr. Ettore Appella (National Cancer Institute). The AC88 monoclonal IgG against hsp90 and the anti-hsp70 monoclonal were from StressGen (Victoria, BC, Canada). The LA-069 anti-Ras and N2-17 anti-Src monoclonal IgGs were from Quality Biotech (Rockville, MD). The C-12 rabbit anti-Raf serum was from Santa Cruz Biotechnology (Santa Cruz, CA). The T7-Tag monoclonal IgG used to immunoadsorb polyhistidine-tagged Mek or Erk was from Novagen (Madison, WI). The rabbit antiserum raised against a GST-Erk fusion protein used for immunoblotting Erk and the baculovirus encoding murine erk1 were kindly provided by Dr. Stuart Decker (Parke-Davis Pharmaceutical Research Division, Ann Arbor, MI). The anti-Raf rabbit antiserum was prepared against a peptide corresponding to the carboxyl-terminal 12 amino acids of human Raf-1 (32). The DS14F5 anti-p60 monoclonal mouse IgG was a kind gift from Dr. David Smith (University of Nebraska, Omaha, NE). Human recombinant EGF was purchased from PeproTech (Rocky Hill, NJ). Purified recombinant Mek1 (33) and purified Erk K52R mutant were kindly provided by Dr. Thomas Sturgill (University of Virginia, Charlottesville, VA). Geldanamycin was obtained from the Drug Synthesis and Chemistry Branch of the Developmental Therapeutics Program, National Cancer Institute.

Methods

Cell Culture and Infection

Recombinant baculoviruses containing the complete coding sequences of chicken c-src (34), murine v-ras (3), human c-raf-1 (5), murine mek1 (35), or murine erk1 cDNAs were used to infect Sf9 insect cells as described elsewhere (34). Cytosol was prepared from infected cells by rupturing them with a Dounce homogenizer in a low salt HE buffer (10 mM HEPES, pH 7.35, 2 mM EDTA) containing 20 mM sodium molybdate. 3Y1 rat fibroblasts stably transfected with DNA encoding v-Raf were cultured in Dulbecco's modified Eagle's medium plus 10% bovine calf serum, and HeLa cells were maintained in Dulbecco's modified Eagle's medium plus 10% fetal calf serum.

Immunoadsorption

Aliquots (100 µl) of infected Sf9 cytosol were immunoadsorbed with the indicated antibody prebound to 8 µl of protein A-Sepharose. To isolate native signaling protein heterocomplexes from cytosol prepared from Sf9 cells infected with several recombinant baculoviruses, the immunoadsorbed pellets were washed by suspension and centrifugation three times in 1 ml of TEG buffer (10 mM TES, 50 mM NaCl, 4 mM EGTA, 10% glycerol, pH 7.6) plus 0.1% Triton X-100. To isolate native signaling protein-hsp90 heterocomplexes, the TEG buffer contained 20 mM sodium molybdate and Triton X-100 was excluded. In the set of experiments shown in Fig. 2, 50-100-µl aliquots of cytosols prepared from Sf9 cells infected with a single recombinant baculovirus were mixed together for 20 min at 0 °C, the proteins were immunoadsorbed to protein A-Sepharose and washed with TEG buffer plus 0.1% Triton X-100.


Fig. 2. Binding of individual signaling proteins to each other. Aliquots (50-100 µl) of cytosol from cells expressing Src, Ras, Raf, Mek, or Erk were mixed for 20 min at 0 °C such that all possible pairs of signaling proteins were exposed to each other. Each pair mixture was then immunoadsorbed with protein A-Sepharose prebound with the appropriate nonimmune IgG, preimmune rabbit serum, anti-Src or anti-Ras monoclonal IgG, T7-Tag monoclonal IgG for Mek and Erk, or Raf antiserum. Immunoadsorbed proteins were resolved by SDS-PAGE and Western blotting. In each set of immunoblots the immunoadsorbed protein is indicated above each pair of nonimmune (N) and immune (I) adsorptions. The protein band that is immunoblotted is indicated to the left. The results are summarized by the circles above each data set: two circles joined by solid interface means that coimmunoadsorption was detected with both of the antibodies directed against each member of the pair; circles joined by a hatched interface means that coimmunoadsorption was seen with only one antibody of the pair; separated circles mean no coimmunoadsorption was seen with either antibody. For reasons discussed in the text, the Mek/Erk combination could only be tested with one antibody.
[View Larger Version of this Image (34K GIF file)]


Reconstitution of Signaling Protein-hsp90 Heterocomplexes

Immune protein A-Sepharose pellets were first stripped of any signaling protein-associated insect hsp90 by suspending the pellets in 1 ml of TEG buffer containing 0.5 M NaCl (but without molybdate) for 1 h at 0 °C followed by two washes with 1 ml of TEG buffer. The stripped immune pellets were then mixed with 100 µl of rabbit reticulocyte lysate, and the mixture was suspended by trituration and incubated 20 min at 30 °C. Following the incubation in reticulocyte lysate, all pellets were washed 3 times with 1 ml of TEG buffer containing 20 mM sodium molybdate.

Gel Electrophoresis and Western Blotting

The immunoadsorbed protein A-Sepharose pellets were heated in SDS sample buffer, and proteins were resolved on 7 or 12% (for Ras) SDS-polyacrylamide gels and transferred to Immobilon-P membranes (17). Membranes were probed with 0.02% rabbit antiserum against hsp70 and hsp90 to detect heat shock proteins, 0.1% anti-Raf serum to detect Raf, 1 µg/ml LA-069 to detect Ras, 1 µg/ml N2-17 to detect Src, or 0.5 µg/ml T7-Tag antibody to detect polyhistidine-tagged Mek, or 0.1% of rabbit antiserum against GST-Erk to detect Erk. To visualize immunoreactive bands, the immunoblots were incubated a second time with the appropriate horseradish peroxidase-labeled counterantibody and color was developed. The blots were then incubated with the appropriate 125I-labeled counterantibody and exposed to film for autoradiography.

Assay of Raf Kinase Activity

Prior to treatment, 100-mm dishes containing confluent HeLa cells were washed once with sterile phosphate-buffered saline and then incubated in serum-free Dulbecco's modified Eagle's medium. After 16 h of serum starvation, cells were pretreated for 4 h with 2 µM geldanamycin or Me2SO vehicle and then for 5 min with 50 ng/ml human recombinant EGF. Cultures were washed once with phosphate-buffered saline, harvested, and lysed in 1 ml of 20 mM HEPES, pH 7.45, 10 mM beta -glycerophosphate, 10 mM MgCl2, 1 mM EDTA, 1% Triton X-100. Lysates were clarified by centrifuging for 10 min in a precooled Microfuge. Replicate aliquots of HeLa lysate were rotated for 1 h at 4 °C with 20 µl of C-12 anti-Raf serum plus 20 µl of a 50% slurry of protein A-Sepharose. The immune pellets were washed twice with 1 ml of lysis buffer and all liquid was aspirated from the pellet without allowing the pellet to dry. Thirty-five µl of Raf kinase assay mixture (0.2 mM nonradioactive ATP, 30 mM MgCl2, 2 mM MnCl2, 40 mM sodium beta -glycerophosphate, 0.2 mM sodium orthovanadate, 2 µM okadaic acid, 0.2% beta -mercaptoethanol) and 1 µg of purified recombinant human Mek1 were added to each Raf immune pellet, and the mixture was incubated for 10 min at 30 °C. To each incubation was added [32P]ATP (20 µCi) followed by 1 µg of purified Erk K52R mutant (kinase dead), and the incubation was continued for 2 min at 30 °C. The reaction was terminated by addition of 5 × sample buffer and boiling, and proteins were resolved by electrophoresis on 10% SDS-polyacrylamide gels and transferred to an Immobilon-P membrane. The membrane was cut and 32P-labeled Erk was detected with a PhosphorImager. The other half of the membrane was Western blotted for Raf using a monoclonal antibody from Transduction Labs, and bands were developed by counter blotting with 125I-labeled goat anti-mouse secondary antibody. This portion of the immunoblot was also exposed to the PhosphorImager screen to normalize the Erk radioactivity to the amount of Raf immunoadsorbed in order to generate the data of the bar graph in Fig. 7A.


Fig. 7. Effect of geldanamycin treatment of 3Y1 cells on the amount of Raf, hsp90, and Raf-associated proteins. A, geldanamycin treatment decreases the amount of Raf but not hsp90 present in cytosol. Cytosols were prepared from 3Y1 cells treated for 3, 6, and 9 h with 10 µM geldanamycin or for 9 h with 0.1% Me2SO vehicle (0 h control). Proteins from 5 µl of cytosol were resolved by SDS-PAGE and Western blotting for Raf and hsp90. The Western blots were then probed with 125I-labeled counterantibody, and the bands were excised and counted to determine the relative amount of Raf (black-square) and hsp90 (bullet ). The autoradiogram above the graph presents the cytosolic Raf and hsp90 that were used to generate the graph. B, geldanamycin affects the amount of hsp90, hsp70, and p60 coimmunoabsorbed with Raf. Cytosols were prepared from 3Y1 cells treated for 4 h with vehicle (lanes 1 and 2) or 10 µM geldanamycin (lanes 3 and 4) and immunoabsorbed with preimmune rabbit antiserum (lanes 1 and 3) or with anti-Raf serum (lanes 2 and 4) and the proteins were resolved.
[View Larger Version of this Image (17K GIF file)]


Luciferase Expression Assay

For each data point, HeLa cells growing in a 100-mm dish at 75% of confluency were transfected by electroporation with 5 µg of an interferon-stimulated response element derived from the interferon-responsive gene ISG15 and linked 5' to a thymidine kinase minimal promoter-luciferase reporter (36). The cells were then incubated 4 h in Dulbecco's modified Eagle's medium with 10% fetal calf serum, and geldanamycin or vehicle was added. One hour later, 50 ng/ml EGF was added and cells were incubated for an additional 5 h before preparation of cell lysates and assay of luciferase activity by luminometer. EGF can activate transcription through the signal tranducers and activators of transcription proteins, which interact with interferon-stimulated response elements. Phosphorylation of signal tranducers and activators of transcription serine residues (37) and MAP kinase (Erk) activity (38) are required for this activation.


RESULTS

Protein-Protein Interactions between Signaling Proteins

Sf9 cells were infected with wild-type baculovirus or with recombinant baculoviruses containing the cDNA for Ras, Src, Raf, Mek, or Erk and aliquots of cytosol were immunoblotted with antibody directed against the expressed protein (Fig. 1). To determine the complexes between signaling proteins that can be accounted for by direct protein-protein interactions, cytosols prepared from Sf9 cells expressing a single signaling protein were mixed in all possible combinations of protein pairs and immunoadsorbed with antibodies against each member of the pair. The immunopellets were Western blotted for each member of the pair to determine by coimmunoadsorption the existence of protein-protein complexes that formed when solutions (cytosols) containing the signaling proteins were mixed. The circles above each set of immunoblots in Fig. 2 summarize the results.


Fig. 1. Western blots of cytosols prepared from infected Sf9 cells. Aliquots (20 µl) of cytosol prepared from Sf9 cells infected with recombinant baculovirus encoding the signaling protein indicated above each set of lanes were resolved by SDS-PAGE and Western blotted with the appropriate antibody against the expressed protein. Lane 1, cytosol from Sf9 cells infected with wild-type baculovirus; lane 2, cytosol from Sf9 cells infected with recombinant baculovirus expressing the indicated protein.
[View Larger Version of this Image (73K GIF file)]


Immunoadsorption of a Raf/Mek mixture with antibody against either component yielded coimmunoadsorption of the other component (indicated by the solid interface between the two circles). Evidence for Ras·Src, Ras·Raf, and Src·Raf protein complexes is based upon coimmunoadsorption being detected with antibody against one member of the pair but not with the other (indicated by the hatched interface between the two circles). For all other signaling protein mixtures, no evidence for a complex was obtained by coimmunoadsorption with antibody against either member of the pair. We have available baculoviruses containing cDNA for either polyhistidine-tagged or untagged Erk but only for polyhistidine-tagged Mek, and the only way we can immunoadsorb Erk is by immunoadsorbing the His-tagged Erk with the T7-Tag monoclonal antibody, which also immunoadsorbs the His-tagged Mek. Thus, the possibility of a Mek-Erk interaction could only be tested with one immunoadsorbing antibody and, as indicated in Fig. 2, coimmunoadsorption was not observed.

As a Src-Ras interaction has not been previously reported, we were surprised to find coimmunoadsorption of Src with the anti-Ras monoclonal antibody. It should be emphasized that we do not know whether this coimmunoadsorption reflects a direct protein-protein interaction between Src and Ras or an indirect interaction through one or more Sf9 cell proteins.

Recovery of Multiprotein Complexes from Sf9 Cells Expressing Four Signaling Proteins

To determine whether multiprotein complexes were formed between signal proteins, Sf9 cells were co-infected simultaneously with baculoviruses containing cDNAs for Ras, Raf, Mek, and Erk. Cytosols prepared from cells expressing all four proteins were then immunoadsorbed to protein A-Sepharose with antibodies specific for Mek, Ras, or Raf. As shown in Fig. 3, immunoadsorption of Mek yielded coimmunoadsorption of Raf (lane 2) but not Erk or Ras. Immunoadsorption with a monoclonal antibody against Ras yielded coimmunoadsorption of Raf and Erk but not Mek (Fig. 3, lane 3). Immunoadsorption of Raf with a rabbit antiserum yielded immune-specific coimmunoadsorption of Mek and a small amount of Ras but not Erk (cf. lanes 4 and 5).


Fig. 3. Immunoadsorption of native signaling protein complexes from baculovirus-infected Sf9 cells. Cytosol was prepared from Sf9 cells infected simultaneously with baculoviruses encoding Ras, Raf, Erk, and polyhistidine-tagged Mek. Aliquots (100 µl) of cytosol were immunoadsorbed to protein A-Sepharose pellets prebound with nonimmune IgG (lane 1), anti-T7 Tag monoclonal IgG to immunoadsorb Mek (lane 2), anti-Ras monoclonal IgG (lane 3), preimmune rabbit serum (lane 4), and rabbit anti-Raf serum (lane 5). Samples were resolved by SDS-PAGE and immunoblotted for Ras, Raf, Erk, and Ras as indicated on the left of the Fig. The symbols hc and lc on the right indicate antibody heavy chain and light chain, respectively.
[View Larger Version of this Image (46K GIF file)]


It is not clear why all four proteins are not brought down with all three antibodies. All or part of the explanation may reflect blockade of epitopes by other proteins in the complex. For example, the polyhistidine-tagged region of Mek may be blocked when Mek is in a complex with three other proteins but not when it is bound only to Raf. Similarly, the epitope for the LA-069 monoclonal antibody against Ras may be blocked when Ras is in a tetrameric complex with the three other proteins but not when it is in a trimeric complex with Raf and Erk. The data of Fig. 3 suggest that both a trimeric Ras·Raf·Erk (Fig. 3, lane 3) complex and a trimeric Ras·Raf·Mek (Fig. 3, lane 5) complex can be isolated. However, it is possible that no more than binary complexes exist. For example, coimmunoadsorption of Raf and Erk with Ras could reflect immunoadsorption only of Ras·Raf and Ras·Erk complexes rather than immunoadsorption of a Ras·Raf·Erk trimer. But, considering that Ras and Raf bind to each other when mixed together (Fig. 2), it is likely that at least some of the coimmunoadsorbed Raf is in ternary complex with Ras and Erk. Also, considering the existence of a quaternary Ras·Raf·Mek·Erk complex that is implied by the elegant work of Moodie et al. (12), it is reasonable to propose the existence of ternary as well as binary complexes in cytosol prepared from cells expressing all four of the signaling proteins.

Comparing the cytosol mixing results of Fig. 2 with the data of Fig. 3 derived from immunoadsorption of cytosol of cells simultaneously expressing Ras, Raf, Mek, and Erk, we can account for the Raf-Mek interactions seen in lanes 2 and 5 of Fig. 3 on the basis of the direct protein-protein binding occurring upon mixture of the two proteins in the experiment of Fig. 2. We can also account for a Ras-Raf interaction but not for the coadsorption of Erk in Fig. 3 (lane 3), either as a Ras·Erk binary complex or as a Ras·Raf·Erk ternary complex. Indeed, in Fig. 2, we see no interaction of Erk with any of the signaling proteins using the pair binding format.

Sf9 Cellular Factors May be Required for the Presence of Erk in a Multiprotein Complex

It is possible that Erk is only bound when multiple proteins are present. Thus in the experiment of Fig. 4A, we have compared the signaling protein complex detected by immunoadsorption with anti-Ras antibody after mixture of cytosols containing singly-expressed Ras, Raf, Mek, and Erk with the complex obtained after immunoadsorption of cytosol from Sf9 cells expressing all four proteins simultaneously. As shown in lane 2 of Fig. 4A, mixture of the four proteins yields coimmunoadsorption of Raf with Ras. Neither Mek nor Erk are present in the immunopellet. As in lane 3 of Fig. 3, however, immunoadsorption of Ras from cytosol of Sf9 cells expressing all four proteins yields coimmunoadsorption of both Raf and Erk (Fig. 4A, lane 4).


Fig. 4. Cellular factors are required to form a signaling protein complex containing Erk. A, a ternary complex containing Erk is obtained from Sf9 cells infected simultaneously with four signaling proteins but not after mixture of the four proteins in vitro. Aliquots of cytosol expressing Ras, Raf, Mek, or Erk were mixed together to yield a solution containing all four proteins and incubated at 0 °C for 20 min (lanes 1 and 2). Aliquots of this mixture and aliquots of cytosol prepared from Sf9 cells infected simultaneously with baculoviruses encoding Ras, Raf, Mek, and Erk (lanes 3 and 4) were immunoabsorbed with nonimmune mouse IgG (lanes 1 and 3) or the LA-069 monoclonal IgG against Ras (lanes and 4) and the immunoabsorbed proteins were resolved by SDS-PAGE and Western blotting. B, simultaneous expression of Ras and Erk yields a binary complex. Aliquots of cytosol prepared from Sf9 cells infected simultaneously with baculoviruses encoding Ras, Raf, and Erk (lanes 1 and 2) or Ras and Erk (lanes 3 and 4) were immunoabsorbed with nonimmune IgG (lanes 1 and 3) or anti-Ras (lanes 2 and 4) and the immunoabsorbed proteins were resolved.
[View Larger Version of this Image (27K GIF file)]


Although Raf and Mek associate with each other to form a stable complex (Fig. 2 and Refs. 8 and 10), Mek is not coimmunoadsorbed in the complex with Ras, Raf, and Erk from cytosol of cells expressing all four proteins. Nevertheless, we examined if the simultaneous expression of Mek was required for formation of a ternary complex containing Erk. In the experiment of Fig. 4B, Ras was immunoadsorbed from cytosol prepared from Sf9 cells simultaneously expressing Ras, Raf, and Erk and Erk was coimmunoadsorbed (lane 2), showing that expression of Mek is not required for Erk coimmunoadsorption. In this experiment we also immunoadsorbed Ras from cytosol prepared from Sf9 cells simultaneously expressing only Ras and Erk (Fig. 4B, lane 4) and Erk was coimmunoadsorbed with Ras. If only Erk is expressed, no Erk is immunoadsorbed by the anti-Ras antibody. This indicates that Raf is not required for the presence of Erk in the complex and that Ras may be the primary site for interaction with Erk.

Because mixing of cytosols containing singly-expressed proteins does not yield a complex containing Erk, while immunoadsorption of Ras from cytosol from Sf9 cells simultaneously expressing multiple proteins yields coimmunoadsorption of Erk, it is reasonable to suggest that Sf9 cellular factors are required to assemble a complex containing Erk. Schulte et al. (27) found that treatment of cells with geldanamycin disrupted both Raf·hsp90 and Raf·Ras complexes, and concluded that association with hsp90 is required for proper localization of Raf in the cell and formation of Ras·Raf complexes. Thus, we wanted to determine whether the hsp90-based chaperone system constituted the Sf9 cellular factors required for the formation of signaling complexes containing Erk.

Association of Src, Raf, and Mek with hsp90

We first wanted to examine what signaling proteins were associated with hsp90. In Fig. 5, the proteins, expressed singly in Sf9 cells, were immunoadsorbed to protein A-Sepharose and the immune pellets were immunoblotted for both the expressed protein and insect hsp90. The cytosols were prepared by rupturing cells in a low salt buffer without detergent but containing sodium molybdate to stabilize the complex with hsp90. These are the conditions we have used previously to demonstrate the Raf·hsp90 complex (19). As shown in lane 3 of Fig. 5, panels A-C, respectively, immunoadsorption of Src, Raf, or Mek yielded coimmunoadsorption of hsp90. The coimmunoadsorption is specific for the presence of the signaling protein because immunoadsorption of the same cytosol with nonimmune antibody (lane 1) or immunoadsorption of cytosol from wild-type baculovirus-infected cells with antibody directed against the signaling protein (lane 2) did not yield hsp90. In contrast to Src, Raf, and Mek, immunoadsorption of Erk (Fig. 5D, lane 3) yields only trace coimmunoadsorption of hsp90, and immunoadsorption of Ras yields no coimmunoadsorption of hsp90 (data not shown).


Fig. 5. Src, Raf, and Mek form native complexes with hsp90 that can be reconstituted in reticulocyte lysate. Aliquots (200 µl) of cytosol prepared from Sf9 cells infected with wild-type baculovirus or baculoviruses expressing Src, Raf, polyhistidine-tagged Mek or polyhistidine-tagged Erk were immunoadsorbed to protein A-Sepharose pellets prebound with the appropriate nonimmune antibody or antibody directed against the signaling protein. Samples in lanes 4-6 were stripped of associated protein with salt and the stripped immunopellets in lanes 5 and 6 were incubated with rabbit reticulocyte lysate as described under "Methods." Immunoadsorbed proteins were resolved by SDS-PAGE and immunoblots were probed with antibodies against hsp90 and the indicated signaling protein. Lane 1, nonimmune immunoadsorption of cytosol from cells expressing the indicated signaling protein; lane 2, immunopellet of cytosol prepared from cells infected with wild-type baculovirus; lane 3, immune pellet from cells expressing the indicated signaling protein; lane 4, salt-stripped immune pellet from cells expressing protein; lanes 5 and 6, stripped nonimmune (lane 5) and immune (lane 6) pellets incubated with reticulocyte lysate. The four panels represent cells expressing Src (A), Raf (B), Mek (C), and Erk (D). The band in the Mek immunoblot in lane 1 of panel C is the lower portion of the heavy chain of the nonimmune IgG.
[View Larger Version of this Image (26K GIF file)]


The insect hsp90 can be stripped off of the immunoadsorbed signaling protein by suspending the immunopellet in salt (Fig. 5, lane 4). When the stripped immunopellet is incubated with rabbit reticulocyte lysate, a heterocomplex with rabbit hsp90 is formed (Fig. 5, panels A-C, lane 6). We are unable to detect any heterocomplex formed between Ras and rabbit hsp90 (data not shown) and we detect only trace formation of an Erk heterocomplex with rabbit hsp90 (Fig. 5D, lane 6).

Geldanamycin Does Not Affect Formation of Erk Signaling Complexes in Sf9 Cells

To determine if the hsp90 chaperone system was required for formation of complexes containing Erk, Sf9 cells simultaneously expressing Ras, Raf, Mek, and Erk were treated for 4 h with 10 µM geldanamycin prior to cytosol preparation and immunoadsorption of Ras. As shown in Fig. 6A, geldanamycin did not affect the amount of Erk or Raf coimmunoadsorbed (cf. lane 6 with lane 3). In Fig. 6B, Sf9 cells expressing Raf were treated with geldanamycin, cytosol was immunoadsorbed with anti-Raf and assayed for coimmunoadsorption of hsp90. Geldanamycin treatment had no apparent effect on the amount of hsp90 coimmunoadsorbed with Raf from Sf9 cytosol (cf. lane 6 with lane 3). However, as reported by Schulte et al. (27) for MCF7 cells, with this geldanamycin treatment in Sf9 cells, we consistently see a decrease of about 50% of the cytosolic Raf (cf. lanes 1 and 4 in Fig. 6, A and B). Although insect hsp90 can be detected with the rabbit antiserum, the reactivity is poor and other antibodies we have tried do not react with the insect hsp90 at all. Thus, it was necessary to utilize a different cell system to study the effect of geldanamycin on the Raf·hsp90 complex.


Fig. 6. Geldanamycin does not cause dissociation of Ras complexes with Raf and Erk. A, geldanamycin has no effect on the Raf or Erk association with Ras in Sf9 cells. Sf9 cells infected simultaneously with baculoviruses encoding Ras, Raf, Mek, and Erk were treated for 4 h with 0.1% Me2SO vehicle (lanes 1-3) or 10 µM geldanamycin (lanes 4-6), and cytosols were immunoabsorbed with nonimmune IgG or anti-Ras. Lane 1, 10 µl of cytosol from cells treated with vehicle; lane 2, nonimmune pellet; lane 3, immune pellet; lane 4, 10 µl of cytosol from cells treated with geldanamycin; lane 5, nonimmune pellet; lane 6, immune pellet. B, geldanamycin has no apparent effect on the amount of Raf-associated hsp90. Sf9 cells infected with Raf were treated for 4 h with vehicle (lanes 1-3) or 10 µM geldanamycin (lanes 4-6). Cytosols were prepared and immunoabsorbed with preimmune rabbit antiserum or rabbit anti-Raf serum. Lane 1, 10 µl of cytosol from cells treated with vehicle; lane 2, nonimmune pellet; lane 3, immune pellet; lane 4, 10 µl of cytosol from cells treated with geldanamycin; lane 5, nonimmune pellet; lane 6, immune pellet.
[View Larger Version of this Image (45K GIF file)]


Effect of Geldanamycin on Raf Stability and Heterocomplex Formation in 3Y1 Cells

To examine the effect of geldanamycin on the cellular content of Raf and formation of Raf·hsp90 complexes, we utilized a rat 3Y1 cell line stably transfected with murine sarcoma virus 3611 DNA encoding v-Raf. In this cell line, we have previously demonstrated native Raf·hsp90 heterocomplexes using the monoclonal AC88 antibody to develop hsp90 (19). As shown in Fig. 7A, a 4-h treatment of 3Y1 cells with geldanamycin causes a loss of about 50% of the cytosolic Raf. A similar decrease was reported in MCF7 cells by Schulte et al. (27) who showed that Raf disappeared from both the cytosolic and membrane fractions. As shown in Fig. 7B, 4 h of geldanamycin treatment caused a loss of some Raf-associated hsp90 and the appearance of Raf-associated hsp70 and p60. The same observation was recently reported by Smith et al. (39) for the effect of geldanamycin on progesterone receptor·hsp90 complexes in COS cells. The Raf and hsp90 bands were cut out of 6 immunoblots such as that of Fig. 7B to assay the relative amount of bound 125I-labeled counterantibody. The mean hsp90:Raf ratio in cells treated with geldanamycin for 4 h was 0.65 (± 0.08 S.E.) of that in vehicle-treated cells (p = 0.003). It should be noted that, although the amount of Raf is reduced about 50% by 4 h of geldanamycin treatment (Fig. 7A), the amount of Raf immunoprecipitated is the same as control (Fig. 7B) because of antibody saturation. Although the effect of geldanamycin has been tested here on 3Y1 cells expressing v-Raf-1, we have previously shown that hsp90 binds to the catalytic domain (19), which is shared with c-Raf-1. Thus, it is likely that geldanamycin produces the same effect on normal cellular Raf.

Effect of Geldanamycin on EGF Response in HeLa Cells

To determine the effect of geldanamycin on the functioning of a Raf-dependent signal transduction pathway, we examined the effect of the antibiotic on EGF stimulation of Raf kinase activity and expression from a reporter gene in HeLa cells. In Fig. 8A, HeLa cells were treated for 4 h with 2 µM geldanamycin, which were the conditions employed by Schulte et al. (27) in their study of Raf interaction with hsp90 in MCF7 cells. The HeLa cells were then briefly treated with EGF, Raf was immunoadsorbed from the cell lysates and the Raf kinase activity of the immune pellet was assayed by the method of Dent et al. (33). In this assay, Raf first phosphorylates purified recombinant human Mek and the activated Mek then phosphorylates purified, kinase-inactive Erk. It can be seen in Fig. 8A that EGF treatment increases ERK phosphorylation about 2.5-fold (lane 2) and that this stimulation is not inhibited by geldanamycin (lane 3). Aliquots of cytosol from both the control and the geldanamycin-treated HeLa cells were immunoblotted for Raf as in Fig. 7A and the 125I-labeled bands were excised and counted for radioactivity. Geldanamycin decreased the level of cytosolic Raf by an average of 50% in the two experiments of Fig. 8A (data not shown).


Fig. 8. Geldanamycin treatment of HeLa cells impairs EGF signaling. A, geldanamycin does not affect EGF stimulation of Raf kinase activity. HeLa cells were pretreated for 4 h with 2 µM geldanamycin and then treated with EGF for 5 min. Raf was immunoadsorbed from cell lysates and Raf kinase activity was assayed by incubation with purified human recombinant Mek1 and subsequent phosphorylation of the Erk K52R mutant as described under "Methods." The images of 32P-labeled Erk and the relative amount of Raf in each sample determined by Western blotting with a 125I-labeled counterantibody are shown at the top. The bar graph shows the relative phosphorylation of Erk corrected for the amount of Raf in each immune pellet. The bars present the average and range of values from two experiments. Conditions are: 1, untreated cells; 2, cells treated with EGF alone; 3, EGF plus geldanamycin; 4, geldanamycin alone. B, geldanamycin inhibits EGF-mediated induction of luciferase expression. HeLa cells transfected with a luciferase reporter plasmid under the control of an interferon-stimulated response element were treated 6 h with 2 or 10 µM geldanamycin, with EGF being present for the last 5 h. Luciferase activity was assayed as described under "Methods." The values are the means from three experiments with the standard error indicated by the vertical line in the bar. Conditions are: 1, untreated cells; 2, cells incubated with EGF alone; 3, EGF plus 2 µM geldanamycin; 4, EGF plus 10 µM geldanamycin. Condition 2 is different from condition 3 at p < 0.05 and from condition 4 at p < 0.03.
[View Larger Version of this Image (19K GIF file)]


Again, it should be emphasized that the anti-Raf antibody is saturated and geldanamycin treatment could decrease cellular Raf levels without affecting basal or EGF-stimulated Raf kinase activity in the assay of Fig. 8A. Thus, we examined the effect of geldanamycin on the activity of the complete signal transduction pathway by assaying EGF induction of luciferase expression from a reporter gene. As shown in Fig. 8B, EGF treatment increased luciferase activity (lane 2) and geldanamycin pretreatment blunted this increase (lanes 3 and 4).


DISCUSSION

The concept that components of the MAP kinase cascade may be preassociated with each other in a multiprotein complex is attractive, in that preassociation of the components would be expected to markedly increase the speed of phosphorylation events leading to the ultimate activation of Erk. A model in which such a signalosome complex exists prior to signal reception is quite different and perhaps inherently more efficient than a model in which sequential events somehow "recruit" the individual proteins of the cascade to the membrane. How such a complex might be formed is not known. But, as we describe in the Introduction, evidence for its existence is accumulating in several cell types. Baculovirus-infected Sf9 cells coexpressing multiple mitogenic signaling proteins constitute a useful system for studying protein-protein interactions of potential importance in the formation of such a complex. It is important to note that Agarwal et al. (40) have used this coexpression system to reconstitute signal transduction from the membrane to the nucleus in Sf9 cells. Thus, it is entirely possible that the signaling protein complexes we have identified in this Sf9 system relate to the overall signal transduction process.

In a screen for simple protein-protein interactions between components, we were unable to detect association of Erk with Ras, Raf, Src, or Mek (Fig. 2), and we were unable to create an Erk-containing complex simply by mixing Ras, Raf, Mek, and Erk in solution (Fig. 4A). Yet, from Sf9 cells simultaneously expressing Ras, Raf, Mek, and Erk, we can isolate what seems very likely to be a ternary complex containing Ras, Raf, and Erk (Figs. 3 and 4A). Since Raf and Mek form a stable complex with each other (Figs. 2 and 3 and Refs. 8 and 10), the absence of Mek from a ternary Erk-containing complex may suggest that the presence of Erk decreases the affinity of the Raf-Mek interaction such that Mek dissociates during the immunoadsorption and washing procedure, leaving us with the Ras·Raf·Erk complex. Expression of Mek is not required for formation of the Erk-containing ternary complex (Fig. 4B). Because Erk is coimmunoadsorbed with Ras from cytosol of Sf9 cells simultaneously expressing only Ras and Erk (Fig. 4B), Ras appears to be necessary for the presence of Erk in any higher order complex.

Because the Sf9 cell can make an Erk-containing complex that we do not form by mixing the components in vitro, it would seem that a cellular process is required to form a complex containing Erk. Our detection of native complexes of insect hsp90 with Raf, Mek, and possibly Erk (Fig. 5), suggested that the hsp90 chaperone system might be involved in the assembly of an Erk-containing multiprotein complex. The observation of Schulte et al. (27) that treatment of cells with the hsp90-binding antibiotic geldanamycin causes dissociation of both Raf·hsp90 and Raf·Ras multimolecular complexes led us to examine the effect of geldanamycin on the coadsorption of Raf and Erk when Ras was immunoadsorbed from cytosol of Sf9 cells coexpressing multiple mitogenic signaling proteins. Geldanamycin did not affect recovery of the Ras·Raf·Erk complex (Fig. 6A), but as reported by Schulte et al. (27), the amount of cytosolic Raf was decreased with geldanamycin treatment (Fig. 6, A and B). Schulte et al. (27) found that geldanamycin treatment eliminated the Raf association with hsp90. We did not see a change in Raf binding to hsp90 in Sf9 cells treated with geldanamycin (Fig. 6B), but the rather poor antibody reaction with hsp90 makes the insect cell an inadequate system in which to look for anything less than total elimination of the Raf·hsp90 complex.

When 3Y1 cells were treated with geldanamycin, the amount of hsp90 coimmunoadsorbed with Raf was moderately decreased (35%), but importantly, the Raf heterocomplex was different in that it contained substantial amounts of p60 and hsp70 as well. In a study of the time course of protein association with the progesterone receptor during heterocomplex assembly in reticulocyte lysate, Smith (41) showed that this complex represents an intermediate stage in the receptor·hsp90 heterocomplex assembly process. Smith et al. (39) have now shown that addition of geldanamycin to the reticulocyte lysate assembly system or geldanamycin treatment of intact cells results in a receptor complex with increased hsp70 and p60 and with somewhat decreased hsp90. Proper hsp90 chaperoning is required for the progesterone receptor to bind steroid (41), and both in the reticulocyte lysate and in the intact cell, geldanamycin treatment rapidly inactivated the steroid binding capacity of the receptor (39). Thus, although the receptor complex that is formed in the presence of geldanamycin contains hsp90, it is not the functional (i.e. steroid binding) heterocomplex. As we show in Fig. 7B, treatment of 3Y1 cells with geldanamycin blocks Raf·hsp90 heterocomplex assembly at the same intermediate stage at which it blocks steroid receptor·hsp90 heterocomplex assembly.

Schulte et al. (27) demonstrated that the rate of Raf degradation is increased in MCF7 cells treated with geldanamycin. The levels of both cytoplasmic and membrane-bound Raf decreased at the same rate, with the half-time for Raf disappearance from the cell being about 4 h (27). In 3Y1 cells, geldanamycin treatment also results in the disappearance of Raf with a half-time of about 4 h (Fig. 7A). One interpretation of these data is that Raf·hsp90 complexes are in a dynamic state of assembly and disassembly in the cell, much as has been reported for steroid receptors (41). Binding of geldanamycin to hsp90 allows hsp90 to bind to Raf (or receptors) in the presence of the required p60 and hsp70 components of the heterocomplex assembly system, but the complex cannot proceed from this intermediate state to the mature form, which does not contain p60. When it is in the mature complex with hsp90, the turnover of Raf is much slower than when it is in the geldanamycin-blocked complex, and in geldanamycin-treated cells, Raf is rapidly degraded.

In contrast to Schulte et al. (27) who found that geldanamycin treatment resulted in dissociation of Ras from Raf, we find no effect of the antibiotic on the coimmunoadsorption of Raf or Erk with Ras (Fig. 6A), suggesting that hsp90 is not required for forming complexes between the mitogenic signaling proteins. In addition, we find that geldanamycin does not affect basal or EGF-stimulated Raf kinase activity in HeLa cells (Fig. 8A), but it does reduce overall EGF-mediated signaling as assayed by induction of luciferase expression from an appropriate reporter gene (Fig. 8B). In the experiments of Fig. 8, the Raf level is decreased by 50% in the geldanamycin-treated HeLa cells, and this effect on turnover of Raf and possibly Mek and other components of the signaling pathway might explain the inhibition of EGF signaling by the antibiotic.

Because the three mitogenic signaling proteins Src, Raf, and Mek are bound to hsp90 (Fig. 5), it is important to determine how the chaperone affects their cellular activity. Several observations lead to the conclusion that formation of the Src·hsp90 heterocomplex is critical for Src function. In yeast, expression of v-Src produces growth arrest, and Xu and Lindquist (42) showed that lowering the level of hsp90 expression relieved cell cycle arrest and rescued cell growth in yeast cells expressing v-Src. Also, point mutations in hsp90 have been shown to affect v-Src activity in yeast (43), and a mutation in the yeast DnaJ homolog, Ydj1, was found to rescue v-Src lethality (44). Similar experiments have not been performed for Raf and Mek, but by analogy with Src, hsp90 may be required for their cellular function as well. At this time, it is not known if hsp90 chaperoning plays a role in signaling protein function in the cell beyond stabilization of the proteins to degradation, as observed for Raf (Ref. 27 and Fig. 7A). We would predict that heterocomplex formation with hsp90 is not required for signaling proteins to form complexes with each other or for their intrinsic kinase activity. However, other roles (e.g. in trafficking of signaling proteins) are possible, and both the genetic observations cited above and the results of geldanamycin experiments reported by Schulte et al. (27) and in this paper support the notion that hsp90 chaperoning is required for this signal transduction pathway to operate in the cell.


FOOTNOTES

*   This work was supported by Grants CA28010 (to W. B. P.) and CA55652 (to R. J.) from the National Cancer Institute. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Dept. of Pharmacology, 1301 Medical Science Research Building III, The University of Michigan Medical School, Ann Arbor, MI 48109-0632. Tel.: 313-764-5414; Fax: 313-763-4450.
1    The abbreviations used are: MAP, mitogen-activated protein; hsp, heat shock protein; Src, pp60src; Mek, same protein as MAP kinase kinase; Erk, extracellular signal-regulated kinase (same protein as MAP kinase); EGF, epidermal growth factor; PAGE, polyacrylamide gel electrophoresis; TES, 2-{[2-hydroxy-1,1-bis(hydroxymethyl) ethyl]amino}ethanesulfonic acid; GMP-PNP, guanosine 5'(beta ,alpha -imino)triphosphate.

Acknowledgments

We thank Stuart Decker for providing antibodies and Erk baculovirus, Tom Roberts for the v-Ras baculovirus, Tom Sturgill for purified Mek1 and ErkK52R, Ettore Appella and David Smith for antibodies, and Eileen Ferguson for manuscript preparation.


REFERENCES

  1. Egan, S. W., and Weinberg, R. A. (1993) Nature 365, 781-783 [CrossRef][Medline] [Order article via Infotrieve]
  2. Crews, C. M., and Erikson, R. L. (1993) Cell 74, 215-217 [Medline] [Order article via Infotrieve]
  3. Williams, N. G., Roberts, T. M., and Li, P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2922-2926 [Abstract]
  4. Fabian, J. R., Vojtek, A. B., Cooper, J. A., and Morrison, D. K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5982-5986 [Abstract]
  5. Pumiglia, K., Chow, Y-H., Fabian, J., Morrison, D., Decker, S., and Jove, R. (1995) Mol. Cell. Biol. 15, 398-406 [Abstract]
  6. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Cell 74, 205-214 [Medline] [Order article via Infotrieve]
  7. Warne, P. H., Viciana, P. R., and Downward, J. (1993) Nature 364, 352-355 [CrossRef][Medline] [Order article via Infotrieve]
  8. Van Aelst, L., Barr, M., Marcus, S., Polverino, A., and Wigler, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6213-6217 [Abstract]
  9. Hallberg, B., Rayter, S. I., and Downward, J. (1994) J. Biol. Chem. 269, 3913-3916 [Abstract/Free Full Text]
  10. Huang, W., Alessandrini, A., Crews, C. M., and Erikson, R. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10947-10951 [Abstract]
  11. Cleghon, V., and Morrison, D. K. (1994) J. Biol. Chem. 269, 17749-17755 [Abstract/Free Full Text]
  12. Moodie, S. A., Willumson, B. M., Weber, M. J., and Wolfman, A. (1993) Science 260, 1658-1661 [Medline] [Order article via Infotrieve]
  13. Brugge, J. S., Erikson, E., and Erikson, R. L. (1981) Cell 25, 363-372 [Medline] [Order article via Infotrieve]
  14. Courtneidge, S. A., and Bishop, J. M. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 7117-7121 [Abstract]
  15. Brugge, J. S., Yonemoto, W., and Darrow, D. (1983) Mol. Cell. Biol. 3, 9-19 [Medline] [Order article via Infotrieve]
  16. Brugge, J. S. (1986) Curr. Top. Microbiol. Immunol. 123, 1-22 [Medline] [Order article via Infotrieve]
  17. Hutchison, K. A., Brott, B. K., De Leon, J. H., Perdew, G. H., Jove, R., and Pratt, W. B. (1992) J. Biol. Chem. 267, 2902-2908 [Abstract/Free Full Text]
  18. Hutchison, K. A., Stancato, L. F., Jove, R., and Pratt, W. B. (1992) J. Biol. Chem. 267, 13952-13957 [Abstract/Free Full Text]
  19. Stancato, L. F., Chow, Y-H., Hutchison, K. A., Perdew, G. H., Jove, R., and Pratt, W. B. (1993) J. Biol. Chem. 268, 21711-21716 [Abstract/Free Full Text]
  20. Wartmann, M., and Davis, R. J. (1994) J. Biol. Chem. 269, 6695-6701 [Abstract/Free Full Text]
  21. Stancato, L. F., Chow, Y-H., Owens-Grillo, J. K., Yem, A. W., Deibel, M. R., Jr., Jove, R., and Pratt, W. B. (1994) J. Biol. Chem. 269, 22157-22161 [Abstract/Free Full Text]
  22. Pratt, W. B. (1993) J. Biol. Chem. 268, 21455-21458 [Free Full Text]
  23. Smith, D. F., and Toft, D. O. (1993) Mol. Endocrinol. 7, 4-11 [Medline] [Order article via Infotrieve]
  24. Hutchison, K. A., Dittmar, K. D., and Pratt, W. B. (1994) J. Biol. Chem. 269, 27894-27899 [Abstract/Free Full Text]
  25. Schumacher, R. J., Hurst, R., Sullivan, W. P., McMahon, N. J., Toft, D. O., and Matts, R. L. (1994) J. Biol. Chem. 269, 9493-9499 [Abstract/Free Full Text]
  26. Dittmar, K. D., Hutchison, K. A., Owens-Grillo, J. K., and Pratt, W. B. (1996) J. Biol. Chem. 271, 12833-12839 [Abstract/Free Full Text]
  27. Schulte, T. W., Blagosklonny, M. V., Ingui, C., and Neckers, L. (1995) J. Biol. Chem. 270, 24585-24588 [Abstract/Free Full Text]
  28. Uehara, Y., Murakami, Y., Mizuno, S., and Kawai, S. (1988) Virology 164, 294-298 [Medline] [Order article via Infotrieve]
  29. Whitesell, L., Shifrin, S. D., Schwab, G., and Neckers, L. M. (1992) Cancer Res. 52, 1721-1728 [Abstract]
  30. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., and Neckers, L. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8324-8328 [Abstract]
  31. Erhart, J. C., Duthu, A., Ullrich, S., Appella, E., and May, P. (1988) Oncogene 3, 595-603 [Medline] [Order article via Infotrieve]
  32. Chow, Y-H., Pumiglia, K. M., Jun, T. H., Dent, P., Sturgill, T. W., and Jove, R. (1995) J. Biol. Chem. 270, 14100-14106 [Abstract/Free Full Text]
  33. Dent, P., Reardon, D. B., Morrison, D. K., and Sturgill, T. W. (1995) Mol. Cell. Biol. 15, 4125-4135 [Abstract]
  34. Park, S., Marshall, M. S., Gibbs, J. B., and Jove, R. (1992) J. Biol. Chem. 267, 11612-11618 [Abstract/Free Full Text]
  35. Dent, P., Chow, Y-H., Wu, J., Morrison, D. K., Jove, R., and Sturgill, T. W. (1994) Biochem. J. 303, 105-112 [Medline] [Order article via Infotrieve]
  36. Pine, R., Canova, A., and Schindler, C. (1994) EMBO J. 13, 158-167 [Abstract]
  37. Wen, Z., Zhong, Z., and Darnell, J. E. (1995) Cell 82, 241-250 [Medline] [Order article via Infotrieve]
  38. David, M., Petricoin, E., Benjamin, C., Pine, R., Weber, M. J., and Larner, A. C. (1995) Science 269, 1721-1723 [Medline] [Order article via Infotrieve]
  39. Smith, D. F., Whitesell, L., Nair, S. C., Chen, S., Prapapanich, V., and Rimerman, R. A. (1995) Mol. Cell. Biol. 15, 6804-6812 [Abstract]
  40. Agarwal, S., Corbley, M. J., and Roberts, T. M. (1995) Oncogene 11, 427-438 [Medline] [Order article via Infotrieve]
  41. Smith, D. F. (1993) Mol. Endocrinol. 7, 1418-1429 [Abstract]
  42. Xu, Y., and Lindquist, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7074-7078 [Abstract]
  43. Nathan, D. F., and Lindquist, S. (1995) Mol. Cell. Biol. 15, 3917-3925 [Abstract]
  44. Kimura, Y., Yahara, I., and Lindquist, S. (1995) Science 268, 1362-1365 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.